GUY JOSE BENDAÑA-GUERRERO & ASOCIADOS named top IP Law Firm in Nicaragua in the 2017 distinguished publications of The Legal 500 and Chambers and Partners. Partners Guy José Bendaña-Guerrero and Julián J. Bendaña-Aragón were chosen as the top IP lawyers.
The Legal 500 describes the firm as follows: “Fielding the largest IP team in Nicaragua, the ‘Very strong’ boutique offering Guy José Bendaña-Guerrero & Asociados has been present in the market for a remarkable 109 years. The group’s tremendous reputation is built on deep expertise and experience in all contentious and non-contentious IP matters, including patents, trade marks and copyright, but also regulatory matters such as sanitary registrations. The client base is mainly composed of renowned international corporations such as Pfizer, Kimberly-Clark, Toyota and Levi Strauss & Co., but also includes several local companies. Key team members Julián Bendaña-Aragón and Guy Bendaña-Guerrero are both highly recommended.”
Chambers & Partners describes the firm as follows: “Esteemed player in the IP field respected for its ample experience across an extensive range of matters, spanning trade marks, patents, copyrights and industrial designs. Team also offers significant capabilities in infringement litigation cases. Maintains an impressive client portfolio featuring distinguished names from the international market. It is clear from the work of this firm that it is one of the best - the lawyers go into great depth, and it is a very well-structured team. Leading practitioner Guy José Bendaña-Guerrero is widely endorsed as a prestigious figure in the IP field, with interviewees stating: "When I have a highly complex issue that requires a top-tier lawyer, I go to him." He offers broad expertise across the field, including in copyright, patent and trade mark law. Key partner Julián Bendaña-Aragón is highlighted by market sources as a strong practitioner in this field. He offers noteworthy expertise relating to patents and trade marks, and is particularly experienced in advising major pharmaceutical companies.”